Advertisement

Comparison of Dabigatran Versus Warfarin Treatment for the Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation

Published:October 07, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.08.038
      Atrial fibrillation is one of the most common arrhythmias in the United States and is associated with an increased risk of thromboembolic events.
      • Tsai CT
      • Liao JN
      • Chen SJ
      • Jiang YR
      • Chen TJ
      • Chao TF.
      Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
      The American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines recommend oral anticoagulation with either warfarin or oral non-vitamin K antagonists for patients diagnosed with atrial fibrillation with a high risk for ischemic stroke based on the CHA2DS2-VASc score.
      • Cheung CC
      • Nattel S
      • Macle L
      • Andrade JG.
      Management of atrial fibrillation in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines.
      The recently published article “Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation” discussed the efficacy of dabigatran versus warfarin in preventing embolic events in valvular atrial fibrillation.
      • Cho MS
      • Kim M
      • Lee Sah
      • Lee S
      • Kim DH
      • Kim J
      • Song JM
      • Nam GB
      • Kim SJ
      • Kang DH
      • Choi KJ
      Comparison of dabigatran versus warfarin treatment for prevention of new cerebral lesions in valvular atrial fibrillation.
      After careful reflection, we would like to provide the following comments.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tsai CT
        • Liao JN
        • Chen SJ
        • Jiang YR
        • Chen TJ
        • Chao TF.
        Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
        Eur J Clin Investig. 2021; 51e13488https://doi.org/10.1111/eci.13488
        • Cheung CC
        • Nattel S
        • Macle L
        • Andrade JG.
        Management of atrial fibrillation in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines.
        Can J Cardiol. 2021; 37: 1607-1618
        • Cho MS
        • Kim M
        • Lee Sah
        • Lee S
        • Kim DH
        • Kim J
        • Song JM
        • Nam GB
        • Kim SJ
        • Kang DH
        • Choi KJ
        Comparison of dabigatran versus warfarin treatment for prevention of new cerebral lesions in valvular atrial fibrillation.
        Am J Cardiol. 2022; 175: 58-64